Advanced glycation end-products and atherosclerosis

Annals of Medicine

Volumn 28, Issue 5, 1996, Pages 419-426

  Vlassara, Helen ^a  

^a PICOWER INST FOR MEDICAL RESEARCH   (United States)

Author keywords

Atherosclerosis; Diabetic complications; Receptors; Vascular disease

Indexed keywords

CREATININE; LOW DENSITY LIPOPROTEIN;

AGING; ARTICLE; ATHEROSCLEROSIS; CREATININE CLEARANCE; DIABETES MELLITUS; GLOMERULOSCLEROSIS; GLYCATION; KIDNEY CLEARANCE; PRIORITY JOURNAL; PROTEIN METABOLISM; TISSUE REPAIR;

EID: 0029793997     PISSN: 07853890     EISSN: None     Source Type: Journal    
DOI: 10.3109/07853899608999102     Document Type: Article

References (60)

1. Bucala R, Vlassara H, Cerami A. Advanced glycosylation endproducts, In: Harding JJ, Crabbe MJC, eds. Post Translational Modification of Proteins, Vol. 2. Boca Raton, FL: CRC Press, 1992: 53-9.
2. Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. J Lab Invest 1994; 70: 138-51.
3. Dyer DG, Blackledge JA, Katz BM, et al. The Maillard Reaction In vivo. Z Ernahrungswiss 1991; 30: 29-45.
4. Bailey AJ, Sims TJ, Avery NC, Miles CA. Chemistry of collagen cross-links - glucose-mediated covalent cross-linking of type-IV collagen in lens capsules. Biochem J 1993; 296: 489-96.
5. Dyer DG, Blackledge JA, Thorpe SR, Baynes JW. Formation of pentosidine during nonenzymatic browning of proteins by glucose - identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 1991; 266: 11654-60.
6. Fu MX, Well-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose: kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 1994; 43: 676-83.
7. Vlassara H, Bucala R. Advanced glycation and diabetes complications; an update. Diabetes Annual 9, 1995.
8. Nakamura K, Hasegawa T, Fukunaga Y, Lenaga K. Crosslines A and B as candidates for the fluorophores in age- and diabetes-related cross-linked proteins, and their diacetates produced by Maillard reaction of I-N-acetyl-L-lysine with D-glucose. J Chem Soc Chem Commun 1992: 992-4.
9. Nakayama H, Taneda S, Kuwajima S, et al. Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Comm 1989; 162: 740-5.
10. Horiuchi S, Araki N, Morino Y. Immunochemical approach to characterize advanced glycation endproducts of the Maillard Reaction. J Biol Chem 1991; 266: 7329-32.
11. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation endproducts in vivo. J Biol Chem 1992; 267: 5133-8.
12. Brownlee M, Vlassara H, Kooney A, Ulrich P, Cerami A. Aminoguanidine prevents diabetes-induced arterial wall protein crosslinking. Science 1986; 232: 1629-32.
13. Bucala R, Makita Z, Koschinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation. Pathway for lipid oxidation in vivo. Proc Natl Acad Sci USA 1993; 90: 6434-8.
14. Bucala R, Makita Z, Vega G, et al. Modification of LDL by advanced glycosylation endproducts contributes to the dyslipidemia of diabetes and renal insufficiency. Proc Natl Acad Sci USA 1994; 91: 9441-5.
15. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J Clin Invest 1991; 87: 432-8.
16. de Tejada IS, Goldstein I, Azadzoi K, Krane RJ, Cohen RJR. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle in diabetic men with impotence. N Engl J Med 1989; 320: 1025-30.
17. McVeigh GE, Brennan GM, Johnston GD, et al. Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-6.
18. Gascho JA, Fanelli C, Zelis R. Aging reduces venous distensibility and the venodilatory response to nitroglycerin in normal subjects. Am J Cardiol 1989; 63: 1267-70.
19. Vlassara H, Fuh H, Makita Z, Krungkrai S, Cerami A, Bucala R. Exogenous advanced glycosylation endproducts induce complex vascular dysfunction in normal animals; a model for diabetic and aging complications. Proc Natl Acad Sci USA 1992; 89: 12043-7.
20. Hogan M, Cerami A, Bucala R. Advanced glycosylation endproducts block the antiproliferative effect of nitric oxide. J Clin Invest 1992; 90: 1110-5.
21. Nicholls K, Mandel TE. Advanced glycosylation endproducts in experimental murine diabetic nephropathy: effect of islet isografting and of aminoguanidine. J Lab Invest 1989; 60: 486-91.
22. Ellis EN, Good BH. Prevention of glomerular basement membrane thickening by aminoguanidine in experimental diabetes mellitus. Metabolism 1991; 40: 1016-9.
23. Soulis-Liparota T, Cooper M, Papazoglou D, Clarke B, Jerums G. Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat. Diabetes 1991; 40: 1328-34.
24. Edelstein D, Brownlee M. Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats. Diabetologia 1992; 35: 96-7.
25. Itakura M, Yoshikawa H, Bannai C, et al. Aminoguanidine decreases urinary albumin and high-molecular-weight proteins in diabetic rats. Life Sci 1991; 49: 889-97.
26. Cho HK, Kozu H, Peyman GA, Parry GJ, Khoobehi B. The effect of aminoguanidine on the blood-retinal barrier in streptozotocin-induced diabetic rats. Ophthalmic Surg 1991; 22: 44-7.
27. Hammes HP, Martin S, Federlin K, Geisen K, Brownlee M. Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy. Proc Natl Acad Sci USA 1991; 88: 11555-8.
28. Hammes H-P, Brownlee M, Edelstein D, Saleck M, Martin S, Federlin K. Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat. Diabetologia 1994; 37: 32-5.
29. Huijberts MSP, Wolffenbuttel BHR, Struijker-Boudier HAJ, Crijns FRL. Aminoguanidine treatment increases elasticity and decreases fluid filtration of large arteries from diabetic rats. J Clin Invest 1993; 92: 1407-11.
30. Huijberts MSP, Wolffenbuttel BHR, Crijns FRL, et al. Aminoguanidine reduces regional albumin clearance but not urinary albumin excretion in streptozotocin-diabetic rats. Diabetologia 1994; 37: 10-4.
31. Kihara J, Schmelzer JD, Podusio JF, Curran GL, Nickander KK, Low PA. Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals. Proc Natl Acad Sci USA 1991; 88: 6107-11.
32. Yagihashi S, Kamijo M, Baba M, Yagihashi N, Nagai K. Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats. Diabetes 1992; 41: 47-52.
33. Cameron NE, Cotter MA, Dines K, Love A. Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin-diabetic rats. Diabetologia 1992; 35: 946-50.
34. Odetti PR, Borgoglio A, De Pascale A, Rolandi R, Adezati L. Prevention of diabetes-increased aging effect on rat collagen-linked fluorescence by aminoguanidine and rutin. Diabetes 1990; 39: 796-801.
35. Oxlund H, Andreassen TT. Aminoguanidine treatment reduces the increase in collagen stability of rats with experimental diabetes mellitus. Diabetologia 1992; 35: 75-8.
36. Makita Z, Vlassara H, Rayfield E, et al. Hemoglobin-AGE. A circulating marker of advanced glycosylation. Science 1992; 258: 651-3.
37. Vlassara H, Brownlee M, Cerami A. High-affinity receptor-mediated uptake and degradation of glucose-modified proteins: a potential mechanism for the removal of senescent macromolecules. Proc Natl Acad Sci USA 1985; 82: 5588-92.
38. Vlassara H, Brownlee M, Cerami A. Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors. J Exp Med 1986; 164: 1301-9.
39. Yang Z, Makita Z, Horii Y, et al. Two novel rat liver membrane proteins that bind advanced glycosylation endproducts: relationship to macrophage receptor for glucose-modified proteins. J Exp Med 1991; 174: 515-24.
40. Kelleher DJ, Kreibich G, Gilmore R. Oligosaccharyltransferase activity is associated with a protein complex composed of ribophorins I and II and a 48 kD protein. Cell 1992; 69: 55-65.
41. Silberstein S, Kelleher DJ, Gilmore R. The 48-kDa subunit of the mammalian oligosaccharyltransferase complex is homologous to the essential yeast protein WBP1. J Biol Chem 1992; 267: 23658-63.
42. r 87,000 protein kinase C substrate from rat brain. J Biol Chem 1987; 262: 16686-91.
43. Sakai K, Hirai M, Minoshima S, Kudoh J, Fukuyama R, Shimizu N. Isolation of cDNAs encoding a substrate for protein kinase C. Nucleotide sequence and chromosomal mapping of the gene for a human 80K protein. Genomics 1989; 5: 309-15.
44. Li Y, Mitsuhashi T, Gilmore R, Vlassara H. Elucidation of advanced glysation receptor components p60/OST-48 K-H (in press).
45. Imani F, Horii Y, Suthanthiran M, et al. Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon-K; role in tissue remodeling. J Exp Med 1993; 178: 2165-72.
46. Libby P, Hansson GK. Involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. J Lab Invest 1991; 64: 5-15.
47. Esposito C, Stern D, Gerlach H, Vlassara H. Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties. J Exp Med 1989; 170: 1387-407.
48. Schmidt AM, Vianna M, Gerlach M, Brett J, Ryan J, Kao J. Isolation and characterization of two binding proteins for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. J Biol Chem 1992; 256: 14987-97.
49. Neeper M, Schmidt AM, Brett J, et al. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J Biol Chem 1992; 267: 14998-5004.
50. Brett J, Schmidt AM, Yan SD, et al. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am J Path 1993; 143: 1699-712.
51. Vlassara H, Li YM, Imani F, et al. Identification of galectin-3 as a high affinity binding protein for advanced glycation endproducts (AGE), a new member of the AGE-receptor complex. Mol Med 1995; 1: 634-46.
52. Li YM, Tan AX, Vlassara H. Antibacterial activity of lysosyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif. Nat Med 1995; 1: 1057-61.
53. Vlassara H, Fuh H, Donnelly T, Cybulsky M. Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits. Mol Med 1995; 1: 447-56.
54. Yang CW, Vlassara H, Peten EP, He CJ, Striker GE, Striker LJ. Advanced glycosylation endproducts upregulate gene expression found in diabetic glomerular disease. Proc Natl Acad Sci USA 1994; 91: 9436-40.
55. Vlassara H, Striker LJ, Teichberg S, Fuh H, Li YM, Steffes M. Advanced glycosylation endproducts induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 1994; 91: 11704-8.
56. Makita Z, Radoff S, Rayfield EJ, et al. Advanced glycosylation endproducts in patients with diabetic nephropathy. N Engl J Med 1991; 325: 836-42.
57. United States Renal Data System. USRDS 1992 Annual Data Report. Bethesda, MD: The National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Disease, August 1992.
58. Makita Z, Bucala R, Rayfield EJ, et al. Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure. Lancet 1994; 343: 1519-22.
59. 2-microglobulin modified with advanced glycation end products is a major component of hemodialysis-associate amyloidosis. J Clin Invest 1993; 92: 1243-52.
60. 2-microglobulin modified with advanced glycation endproducts in the pathogenesis of hemodialysis-associated amyloidosis. J Clin Invest 1994; 93: 521-7.